NCT05419479 - Switch Maintenance in Pancreatic | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

September 30, 2028

Conditions

Pancreatic CancerAdenocarcinoma of the PancreasSquamous Cell Carcinoma of PancreasAdenosquamous Carcinoma of the Pancreas

Interventions

DRUG

ZIMBERELIMAB

Via IV on two days per cycle, dosage per protocol

DRUG

DOMVANALIMAB

Via IV on two days per cycle, dosage per protocol

DRUG

APX005M

Via IV on two days per cycle, dosage per protocol

DRUG

FOLFIRI

every two weeks through an infusion at a dose determined by physician

Trial Locations (1)

RECRUITING

Dana Farber Cancer Institute, Boston